NSE SUNPHARMA · BSE 524715 · Biotechnology & Drugs · NIFTY 50

Sun Pharmaceutical Industries Share Price

Market closed · NSE price as of Mon 28 Sep
₹1,838.00 ▼ −₹14.26 · 0.77%
Day range · 28 Sep
₹1,839.20Low₹1,856.50High
52-week range
₹1,547.25Low · 26 Sep 2025₹2,047.55High · 31 Jul 2026

Sun Pharmaceutical Industries Overview

Where the price stands, how it has moved and how it sits against its averages.

Sun Pharmaceutical Industries shares last traded at ₹1,838.00 on the NSE, down 0.77% on the day. That is 10.2% below the 52-week high of ₹2,047.55 and 18.8% above the 52-week low of ₹1,547.25. The stock trades at 36.46× earnings, above the sector average of 33.72. Its market value is ₹4,40,987 Cr.

NSE closing prices — daily for the last year, weekly before that — ending at the latest price (Mon 28 Sep). Hover, tap or use the arrow keys to read a day.

Price returns

1 Day▼ −0.77%
1 Week▼ −1.65%
This month▼ −7.40%
3 Months▼ −1.33%
6 Months▲ +2.48%
This year▲ +6.88%
1 Year▲ +15.84%

Share price growth a year (CAGR): 3 years ▲ +17.5% · 5 years ▲ +19.0% · 10 years ▲ +8.9%

Against the market: 1 Month ▲ +0.87% · 3 Months ▲ +3.74% · 6 Months ▲ +2.83% · This year ▲ +24.21% · 1 Year ▲ +25.00%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 1 of 6

  1. 50-day average₹1,916.86 ▼ price 4.1% below
  2. 100-day average₹1,884.35 ▼ price 2.5% below
  3. 20-day average₹1,881.05 ▼ price 2.3% below
  4. 5-day average₹1,856.48 ▼ price 1.0% below
  5. 10-day average₹1,851.55 ▼ price 0.7% below
  6. Today's price₹1,838.00
  7. 300-day average₹1,806.49 ▲ price 1.7% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Sun Pharmaceutical Industries Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
58,462
Net profit₹ crore · losses below zero
11,479

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹58,462 Cr ▲ +11.2% ₹11,479 Cr 19.6% ₹46.24 ₹16.00
FY 2025 ₹52,578 Cr ▲ +8.4% ₹10,929 Cr 20.8% ₹45.55 ₹16.00
FY 2024 ₹48,497 Cr ▲ +10.5% ₹9,576 Cr 19.7% ₹39.91 ₹13.50
FY 2023 ₹43,886 Cr ▲ +13.5% ₹8,474 Cr 19.3% ₹35.32 ₹11.50
FY 2022 ₹38,654 Cr ▲ +15.4% ₹3,273 Cr 8.5% ₹13.64 ₹10.00
FY 2021 ₹33,498 Cr ▲ +2.0% ₹2,904 Cr 8.7% ₹12.10 ₹7.50
FY 2020 ₹32,838 Cr — ₹3,765 Cr 11.5% ₹15.69 ₹4.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
23%
77%
  • Total assets₹1,08,785 Cr
  • Total liabilities₹25,215 Cr
  • Shareholders' equity₹83,570 Cr
  • Total debt₹4,627 Cr
  • Cash & investments₹33,534 Cr
  • Current ratio2.82×
  • Revenue growth, 5 yr11.78% a year
  • EPS growth, 5 yr30.74% a year
  • Operating margin (TTM)21.77%
  • Net margin (TTM)19.83%

Cash flow — FY26

Operating activities
▲ ₹12,582 Cr
Investing activities
▼ −₹11,344 Cr
Financing activities
▼ −₹2,513 Cr
Free cash flow
▲ ₹8,973 Cr
Net change in cash
▼ −₹498 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue32,837.5033,498.1438,654.4943,885.6848,496.8552,578.4458,462.04
Cost of revenue10,471.2710,512.5112,410.4312,772.4712,830.4412,947.9113,986.80
Gross profit22,366.2322,985.6326,244.0631,113.2135,666.4139,630.5344,475.24
Operating expenses28,129.1231,351.5235,076.8234,793.3338,479.9240,674.5146,169.60
Operating income4,708.382,146.623,577.679,092.3510,016.9311,903.9312,292.44
Depreciation2,052.782,079.952,143.742,529.432,556.792,575.392,937.85
Profit before tax5,009.592,799.374,481.329,408.4311,087.8913,752.1315,118.88
Tax822.80514.691,075.50847.591,439.452,772.033,939.76
Net profit3,764.932,903.823,272.738,473.589,576.3810,929.0411,479.42
EPS (₹)15.6912.1013.6435.3239.9145.5546.24
Dividend per share (₹)4.007.5010.0011.5013.5016.0016.00

Sun Pharmaceutical Industries vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Sun Pharmaceutical Industries This stock ₹1,838.00 ▼ −0.77% ₹4,40,987 Cr 36.46 5.28 14.22% 19.83% 0.87%
Divi's Laboratories ₹9,531.50 ▼ −0.82% ₹2,53,031 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,869.40 ▼ −2.32% ₹1,85,210 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,388.90 ▼ −0.59% ₹1,12,203 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,212.00 ▲ +0.83% ₹1,20,897 Cr 21.19 4.24 17.90% 18.51% 0.09%
Lupin ₹2,061.85 ▼ −1.35% ₹94,281 Cr 19.12 4.98 12.70% 19.16% 0.74%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Sun Pharmaceutical Industries shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
54.5%
14.5%
12.8%
18.1%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter54.48%54.48%54.48%54.48% 0.00 pts
FII16.55%16.12%15.94%14.54% ▼ −1.40 pts
MF12.41%12.09%11.96%12.84% ▲ +0.88 pts
Other16.56%17.31%17.62%18.14% ▲ +0.52 pts

Sun Pharmaceutical Industries Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Sun Pharmaceutical IndustriesBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
36.46
▲ 8% above the sector average of 33.72
P/E, 12-month rangeLow 27.84 · high 67.41
22%
Today's P/E sits 22% of the way from its low to its high
P/BPrice ÷ book value per share
5.28
P/SMarket cap ÷ last 12 months' revenue
7.36
P/CFPrice ÷ cash flow per share
29.92
PEGP/E ÷ earnings growth rate
3.91

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
80.48%
▲ above its 5-yr average of 73.17%
Operating marginKept after running costs
21.77%
▲ above its 5-yr average of 19.37%
Pre-tax marginKept before tax
26.78%
▲ above its 5-yr average of 22.24%
Net marginKept as profit
19.83%
▲ above its 5-yr average of 18.08%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
14.24%
▲ above its 5-yr average of 14.22%
Return on assetsProfit on everything it owns
11.13%
▲ above its 5-yr average of 10.51%
Return on investmentProfit on long-term capital
14.02%
▲ above its 5-yr average of 13.99%
Return on capital employedProfit before interest and tax on equity + debt
18.58%

Growth Is the business getting bigger?

Revenue — last 12 months
+11.4%
▲ growing
Revenue — 3 yr, a year
+10.0%
▲ growing
Revenue — 5 yr, a year
+11.8%
▲ growing
Net profit — 3 yr, a year
+10.6%
▲ growing
Net profit — 5 yr, a year
+31.6%
▲ growing (off the scale)
EPS — last 12 months
+14.9%
▲ growing
EPS — 3 yr, a year
+9.4%
▲ growing
EPS — 5 yr, a year
+30.7%
▲ growing (off the scale)
Dividend — 3 yr, a year
+11.6%
▲ growing
Book value — 5 yr, a year
+12.5%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.06×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
2.82×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
2.29×
✓ Comfortable
Payout ratioShare of profit paid as dividend
34.60%
✓ Balanced

Per share What each share stands for

EPS (TTM)
₹50.44
Book value
₹348.31
Cash flow
₹61.96
Dividend
₹16.00
Revenue
₹249.89

The share price is 5.28× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 110 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year40.06
Current Dividend Yield - Common Stock Primary Issue, LTM0.86
Price to Book - most recent fiscal year5.32
P/E Basic excluding extraordinary items - TTM37.84
P/E including extraordinary items - TTM36.72
P/E excluding extraordinary items low, trailing 12 months27.84
Price to Tangible Book - most fiscal year7.38
Dividend Yield - 5 Year Average0.96
Price to sales - most recent fiscal year7.60
Dividend Yield - indicated annual dividend divided by closing price0.86
Price to Cash Flow per share - trailing 12 month29.92
Peg Ratio3.91
Price to Free Cash Flow per Share - most recent fiscal year88.20
P/E Normalized, most recent fiscal year36.80
P/E excluding extraordinary items high, trailing 12 months67.41
P/E excluding extraordinary items, most recent fiscal year quarter37.63
Price to sales - trailing 12 month7.42
Net Debt, LFY−2,89,069.50

Per share

Dividend Per Share - 5 year average13.40
Cash Flow per share - trailing 12 month61.96
Cash Flow per share - most recent fiscal year58.84
EPS including extraordinary items - trailing 12 month50.44
EPS including extraordinary items - most recent fiscal year47.84
EBITD per share - trailing 12 month69.72
Revenue/share - trailing 12 month249.89
EPS excluding extraordinary items - trailing 12 month49.22
EPS Basic excluding extraordinary items - most recent fiscal year46.24
EPS Basic excluding extraordinary items - trailing 12 month49.22
Book value per share - most recent fiscal year348.31
Dividend per share - most recent fiscal year16.00
Revenue/share - most recent fiscal year243.66
EPS Normalized - most recent fiscal year50.33
Book value (tangible) per share - most recent fiscal year250.86
Dividends per share - trailing 12 month16.00
EPS excluding extraordinary items - most recent fiscal year46.24
Cash per share - most recent fiscal year139.76

Margins

Operating margin - trailing 12 month21.77
Gross Margin - 5 year average73.17
Operating margin - 1st historical fiscal year21.03
Operating Margin - 5 year average19.37
Net Profit Margin % - 1st historical fiscal year19.12
Gross Margin - 1st historical fiscal year76.08
Net Profit Margin % - trailing 12 month19.83
Net Profit Margin - 5 year average18.08
Pretax Margin - 5 year average22.24
Pretax margin - 1st historical fiscal year25.86
Pretax margin - trailing 12 month26.78
Free Operating Cash Flow/Revenue, 5 Year Average11.03
Gross Margin - trailing 12 month80.48

Growth

EPS Change %, TTM over TTM14.91
Revenue growth rate, 5 year11.78
EPS growth rate, 5 year30.74
Revenue Change % - most recent quarter 1 year ago10.46
Growth rate% - dividend, 3 year11.64
Growth rate% - EPS, 3 year9.40
Revenue/share (5 yr growth)11.78
Free Operating Cash Flow, 5 Year CAGR7.93
Tangible Book Value, Total Equity, 5 Year CAGR11.77
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR12.09
Capital Spending growth rate, 5 year25.27
Revenue Change %, TTM over TTM11.41
Growth rate% - Revenue, 3 year10.03
Book value per share growth rate, 5 year12.46
EPS Change % - most recent quarter 1 year ago32.81
Net Profit Margin growth rate, 5 year22.90
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR14.17
Total Debt, 5 Year CAGR3.65

Financial strength

Free Cash Flow - most recent fiscal year50,386.40
LT debt/equity - most recent fiscal year0.00
Quick ratio - most recent fiscal year2.29
Payout ratio - trailing 12 month10.17
Current ratio - most recent fiscal year2.82
Current EV/Free Cash Flow, LFY63.25
Total debt/total equity - most recent fiscal year0.06
Payout ratio - most recent fiscal year34.38

Returns & efficiency

Return on average equity - 5 year average14.22
Net Income/employee - trailing 12 month25,27,315.00
Revenue/employee - most recent fiscal year1,29,91,560.00
Return on investment - most recent fiscal year14.02
Return on average assets - most recent fiscal year11.13
Receivables turnover - most recent fiscal year4.08
Inventory turnover - most recent fiscal year1.23
Revenue/employee - trailing 12 month1,27,46,920.00
Return on average assets - 5 year average10.51
Net Income/employee - most recent fiscal year24,84,249.00
Asset turnover - most recent fiscal year0.58
Return on average equity - most recent fiscal year14.24
Return on investment - 5 year average13.99

Price & volume

Market Cap4,41,467.23
52 week Low Date26 Sep 2025
Price - 1 Day % Change0.12
Relative (S&P500) price percent change - 13 week3.74
Avg trading volume last 10 days1.55
Price - 13 week price percent change−0.57
Price - 52 week price percent change13.81
Avg Trading Volume Last 3 months41.14
Price - 5 Day % Change0.81
Price % Change Month To Date−6.68
Relative (S&P500) price percent change - 04 week0.87
52 week High Date31 Jul 2026
Price - 26 week price percent change3.27
PDATE25 Sep 2026
Price - YTD price percent change7.70
Relative (S&P500) price percent change - 52 week25.00
NPRICE1,852.20
Relative (S&P500) price percent change - 26 week2.83
52 week Low1,548.00
52 week High2,046.90
Beta0.86
Relative (S&P500) price percent change - Year to Date24.21

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹16.00
₹16.00
  • Dividend yield0.87%
  • Payout ratio34.60%
  • 5-year average dividend₹13.40 a share
  • Latest dividend₹5.00 per share · 7 Jul 2026

Corporate calendar

  • MeetingPostal Ballot
  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • Dividend₹5.00 per share · 500% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • MeetingPostal Ballot
  • Dividend₹11.00 per share · 1,100% · Interim dividend
Show 14 older events
  • BoardQuarterly Results & Interim Dividend
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • Dividend₹5.50 per share · 550% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • Dividend₹10.50 per share · 1,050% · Interim dividend
  • BoardQuarterly Results & Interim Dividend
  • BoardQuarterly Results
  • Dividend₹5.00 per share · 500% · Final dividend
  • Dividend₹8.50 per share · 850% · Interim dividend
  • Dividend₹4.00 per share · 400% · Final dividend
  • Dividend₹7.50 per share · 750% · Interim dividend

About Sun Pharmaceutical Industries

Biotechnology & Drugs

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

Key people

  • Dilip Shantilal ShanghviExecutive Chairman of the Board
  • Jayashree SatagopanChief Financial Officer
  • Aalok Dilip ShanghviWhole-time Director and Chief Operating Officer
  • Anoop Anjanikumar DeshpandeCompliance Officer, Company Secretary
  • Kirti GanorkarManaging Director
  • Vidhi Dilip ShanghviWhole-Time Director

Company facts

  • NSE symbolSUNPHARMA
  • BSE code524715
  • ISININE044A01036
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 50, NIFTY 500
  • Market cap₹4,40,987 Cr
  • Revenue (FY26)₹58,462 Cr
  • Net profit (FY26)₹11,479 Cr

In the News

Recent headlines about Sun Pharmaceutical Industries — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Sun Pharmaceutical Industries (NSE: SUNPHARMA) last traded at ₹1,838.00 on the NSE, down 0.77% (₹14.26) on the day, as of 28 Sep 2026. The day's range was ₹1,839.20 – ₹1,856.50.

Sun Pharmaceutical Industries's 52-week high is ₹2,047.55 (31 Jul 2026) and its 52-week low is ₹1,547.25 (26 Sep 2025). At ₹1,838.00 the share is 10.2% below its high and 18.8% above its low.

Sun Pharmaceutical Industries's market capitalisation is ₹4,40,987 Cr (₹4.41L Cr). It is part of the NIFTY 50 index.

Sun Pharmaceutical Industries's P/E ratio (trailing 12 months) is 36.46. The sector average is 33.72, so investors pay 8% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹50.44.

Sun Pharmaceutical Industries shares are up 15.84% over the last year, up 6.88% so far this year, up 2.48% over 6 months, down 1.33% over 3 months. Over the last year the stock did 25.00% better than the market.

In FY26 (year to Mar 2026), Sun Pharmaceutical Industries reported revenue of ₹58,462 Cr (up 11.19% on the year before) and a net profit of ₹11,479 Cr. Earnings per share were ₹46.24.

Yes. Sun Pharmaceutical Industries's latest dividend is ₹5.00 per share (500%, final dividend), with an ex-date of 7 Jul 2026. The dividend yield is 0.87%. It has paid 8 dividends in the records shown on this page.

As of Jun 2026: Promoter 54.48%, FII 14.54%, MF 12.84%, Other 18.14%.

Sun Pharmaceutical Industries's listed peers in Biotechnology & Drugs include Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences, Lupin. By market capitalisation it ranks #1 of 6 in this group.

No. Sun Pharmaceutical Industries has debt — its debt-to-equity ratio is 0.06 and total debt was ₹4,627 Cr in FY26.